Human leukocyte antigen class I expression: Marker of poor prognosis in uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 9, 1997, Pages 1865-1872

  Blom, Derk Jan R ^a   Luyten, Gregorius P M ^b   Mooy, Cornelia ^b   Kerkvliet, Sonja ^b   Zwinderman, Aeilko H ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Human leukocyte antigen expression; Patient survival; Uveal melanoma

Indexed keywords

HLA ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 0030758286     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Østerlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer. 1987;40:161-164.
2. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-336.
3. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245-250.
4. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 1996;6:11-24.
5. De Waard-Siebinga I, Visseren MJW, Blom DJR, Melief CJM, Jager MJ. Uveal melanoma cells can be lysed by tyrosinase-and MAGE-3-specific CTL clones. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1996;37:S622.
6. Bottino C, Vitale M, Pende D, Biassoni R, Moretta A. Receptors for HLA Class I molecules in human NK cells. Semin Immunol. 1995;7:67-73.
7. Kaufman DS, Schoon RA, Robertson MJ, Leibson PJ. Inhibition of selective signaling events in natural killer cells recognizing major histocompatibility complex class I. Proc Natl Acad Sci. 1995;92:6484-6488.
8. Van Duinen SG, Ruiter DJ, Bröcker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 1988;48:1019-1025.
9. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor aggressiveness and MHC Class I and II antigens in laryngeal and breast cancer. Cancer Biol. 1991;2:47-54.
10. Möller P, Momburg F, Koretz K, et al. Influence of major histocompatibility complex Class I and II antigens on survival in colorectal carcinoma. Cancer Res. 1991;51:729-736.
11. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility Class I and Class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer. 1994;30(A):376-381.
12. Levin I, Klein T, Kuperman O, et al. The expression of HLA Class I antigen in prostate cancer in relation to tumor differentiation and patient survival. Cancer Detect Prev. 1994;18:443-445.
13. Jager MJ, Van Der Pol JP, De Wolff-Rouendaal D, De Jong PTVM, Ruiter DJ. Decreased expression of HLA Class II antigens on human uveal melanoma cells after in vivo X-ray irradiation. Am J Ophthalmol. 1988; 105:78-86.
14. Natali PG, Bigotti A, Nicotra MR, et al. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res. 1989; 49:1269-1274.
15. De Waard-Siebinga I, Houbiers JGA, Hilders CGJM, De Wolff-Rouendaal D, Jager MJ. Differential expression of HLA-A and HLA-B alleles on uveal melanoma as determined by immuno-histology. Ocul Immunol Inflamm. 1996;4:1-14.
16. De Waard-Siebinga I. HLA expression on uveal melanoma and impact on prognosis. In: HLA Antigens in Uveal Melanoma. Haveka B.V. Press, Alblasserdam, The Netherlands. 1996;37-44. Thesis.
17. Falk K, Rötschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351:290-296.
18. Mooy CM, Luyten GPM, De Jong PTVM, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol. 1995;147:1097-1103.
19. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-1398.
20. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A and HLA-B-specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol. 1989;2:113-125.
21. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterisation of certain HLA-C locus products. J Immunol. 1986;137:2299-2306.
22. Cohen EP, Kim TS. Neoplastic cells that express low levels of MHC Class I determinants escape host immunity. Sem Cancer Biol. 1994;5:419-428.
23. Ferrone S, Marincola F. Loss of HLA Class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995;16:487-494.
24. Trinchieri GJ. Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med. 1994;180:417-421.
25. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature. 1995;378:245-248.
26. Ma D, Luyten GPM, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995;36:435-441.
27. Whiteside TL, Herberman RB. Role of human natural killer cells in health and disease. Clin Diag Lab Immunol. 1994;1:125-133.
28. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995;7:704-710.
29. Algarra I, Ohlen C, Perez M, et al. NK sensitivity and lung clearance of MHC-Class-I-deficient cells within a heterogenous fibrosarcoma. Int J Cancer. 1989; 44:675-680.
30. Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31:2106-2110.
31. Whelchel JC, Farah SE, McLean IW, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993;34:2603-2606.
32. De Waard-Siebinga I, Hilders CGJM, Hansen BE, Van Delft J, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefe's Arch Clin Exp Ophthalmol. 1995;234:34-42.
33. Ksander BR, Rubsamen PE, Olsen KR, Cousins SW, Streilein JW. Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. Invert Ophthalmol Vis Sci. 1991;32:3198-3208.
34. Kaiser CJ, Ksander BR, Streilein JW. Inhibition of lymphocyte proliferation by aqueous humor. Reg Immunol. 1989;2:42-49.
35. Apte RS, Niederkorn JY. Effect of a putative suppressor factor in the aqueous humor on natural killer cell activity in vitro. Inv Ophthalmol Vis Sci. 1995;36S:144.
36. Ma D, Niederkorn JY. Transforming growth factor-β down-regulates major histocompatibility complex Class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995;86:263-269.